Thomas P. Dyrberg, M.D., Ph.D., serves as Senior Partner of Novo Ventures and Novo A/S. Thomas Dyrberg joined Novo A/S in December 2000, where he was a Partner. He held research positions at the Hagedorn Research Institute, Gentofte, Denmark and at the Scripps Research Institute, La Jolla, California. In 1990, he joined Novo Nordisk A/S and worked in health care discovery on various aspects of diabetes immunology and pathogenesis and health Care Clinical Drug Development as an International Clinical Project Manager since 1996. He serves as the Deputy Chairman of Veloxis Pharmaceuticals A/S and has been its Director since September 2003. Thomas Dyrberg has been a Director at Gloucester Pharmaceuticals, Inc. since August 25, 2009. He serves as a Director at Rejuvenon, Corp, Allocure Inc., Veloxis, Lux Biosciences, Inc., Ophthotech Corporation, Sapphire Therapeutics Inc., and Delenex Therapeutics AG. He served as a Director of BioMimetic Therapeutics, Inc. from May 2001 to June 21, 2007. He served as a Director of Helsinn Therapeutics (U.S.), Inc. He has published several articles within the fields of diabetes, immunology, and autoimmunity. Thomas Dyrberg has an M.D. degree in 1981 and his DM.Sc. degree from the University of Copenhagen in 1986.